Copyright
©The Author(s) 2025.
World J Gastrointest Surg. May 27, 2025; 17(5): 101605
Published online May 27, 2025. doi: 10.4240/wjgs.v17.i5.101605
Published online May 27, 2025. doi: 10.4240/wjgs.v17.i5.101605
Table 6 Comparative analysis of safety assessment between the two groups, n (%)
Experimental group (n = 45) | Control group (n = 44) | χ2 | P value | |
Adverse reaction | 5 (11.11) | 13 (29.55) | 4.686 | 0.030 |
Decreased appetite | 1 (2.22) | 2 (4.55) | ||
Diarrhea | 1 (2.22) | 1 (2.27) | ||
Headache | 0 (0.00) | 1 (2.27) | ||
Lethargy | 1 (2.22) | 3 (6.82) | ||
Liver function damage | 0 (0.00) | 1 (2.27) | ||
Rash | 1 (2.22) | 1 (2.27) | ||
Abnormal blood pressure | 0 (0.00) | 1 (2.27) | ||
Heart function abnormalities | 0 (0.00) | 1 (2.27) | ||
Reactive telangiectasia | 1 (2.22) | 2 (4.55) |
- Citation: Song T, Wu KH, Yang H, Xie WL, Shen L. Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma. World J Gastrointest Surg 2025; 17(5): 101605
- URL: https://www.wjgnet.com/1948-9366/full/v17/i5/101605.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i5.101605